Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology.
Quote | Delcath Systems Inc. (OTCMKTS:DCTH)
Last: | $12.75 |
---|---|
Change Percent: | 0.0% |
Open: | $12.75 |
Close: | $12.75 |
High: | $12.75 |
Low: | $12.75 |
Volume: | 312 |
Last Trade Date Time: | 04/28/2020 04:45:48 am |
News | Delcath Systems Inc. (OTCMKTS:DCTH)
2024-06-17 07:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-13 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors with any experience in the world of penny stocks know that risk is real. That risk is higher as the price of shares goes lower. Thus, stocks trading between $5 and $10 are somewha...
Message Board Posts | Delcath Systems Inc. (OTCMKTS:DCTH)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $DCTH 23% v573K c6.00 f10,046M H6.27 ML4.24 | znewcar1 | investorshangout | 03/27/2023 9:48:00 PM |
znewcar1: DCTH 23% v1,3M c15.10 f6,2M (note F was 9M in 2019-0614) this has been RS to death. | znewcar1 | investorshangout | 04/05/2021 9:02:16 PM |
znewcar1: DCTH 19% v170K c.12374 f9,M R.15 S.1186 | znewcar1 | investorshangout | 06/14/2019 8:52:15 PM |
znewcar1: DCTH 126% v3,9M c.215 f9,0M H .217 EOD push | znewcar1 | investorshangout | 04/16/2019 8:03:08 PM |
znewcar1: 28.60% v576,177 c.4901 f9,007,952 H.6 interesting | znewcar1 | investorshangout | 11/22/2018 4:44:36 AM |
News, Short Squeeze, Breakout and More Instantly...
2024-06-17 07:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board of...